Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $21,617.35 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $4.15, for a total transaction of $21,617.35. Following the sale, the chief operating officer now owns 211,041 shares in the company, valued at $875,820.15. This represents a 2.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, March 5th, Daniel Lesueur sold 16,902 shares of Health Catalyst stock. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04.
• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $5.76, for a total value of $30,003.84.

Health Catalyst Trading Up 2.6 %

Shares of HCAT traded up $0.10 during trading hours on Friday, reaching $3.93. 437,085 shares of the company traded hands, compared to its average volume of 615,972. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 12 month low of $3.60 and a 12 month high of $9.24. The company has a market capitalization of $275.93 million, a price-to-earnings ratio of -2.91 and a beta of 1.43. The company's fifty day moving average price is $4.65 and its two-hundred day moving average price is $6.51.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on HCAT shares. Stephens lowered their target price on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Evercore ISI cut shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday. Wells Fargo & Company dropped their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada cut their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group decreased their price target on Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.73.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in Health Catalyst by 69.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company's stock worth $4,208,000 after purchasing an additional 211,805 shares during the period. Impax Asset Management Group plc grew its stake in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after buying an additional 195,525 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Health Catalyst by 4.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock valued at $11,749,000 after buying an additional 66,896 shares in the last quarter. State Street Corp lifted its holdings in shares of Health Catalyst by 2.5% in the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company's stock worth $9,473,000 after buying an additional 28,251 shares during the period. Finally, Intech Investment Management LLC raised its stake in Health Catalyst by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 28,386 shares of the company's stock worth $201,000 after buying an additional 10,611 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.